Literature DB >> 21866099

Evaluation of drug interactions in a large sample of psychiatric inpatients: a data interface for mass analysis with clinical decision support software.

P Haueis1, W Greil, M Huber, R Grohmann, G A Kullak-Ublick, S Russmann.   

Abstract

In order to improve medication safety, more epidemiological data on the prevalence and clinical relevance of drug interactions are required. We developed an interface for mass analysis using the Clinical Decision Support Software (CDSS) MediQ and a multidimensional classification (Zurich Interaction System (ZHIAS)) incorporating the Operational Classification of Drug Interactions (ORCA). These were applied to 359,207 cross-sectional prescriptions from 84,607 psychiatric inpatients collected through the international AMSP program. MediQ issued 2,308 "high" and 71,112 "average" danger interaction alerts. Among these, after ORCA reclassification, there were 151 contraindicated and 4,099 provisionally contraindicated prescriptions. The ZHIAS provided further detailed categorical information on recommended management and specific increased risks (QTc prolongation being the most frequent one) associated with interactions. We developed a highly efficient solution for the identification and classification of drug interactions in large prescription data sets; this solution may help to reduce the frequency of overalerting and improve acceptance of the efficacy of CDSS in reducing the occurrence of potentially harmful drug interactions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21866099     DOI: 10.1038/clpt.2011.150

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  13 in total

1.  Comparative evaluation of three clinical decision support systems: prospective screening for medication errors in 100 medical inpatients.

Authors:  Daniela Fritz; Alessandro Ceschi; Ivanka Curkovic; Martin Huber; Marco Egbring; Gerd A Kullak-Ublick; Stefan Russmann
Journal:  Eur J Clin Pharmacol       Date:  2012-02-29       Impact factor: 2.953

2.  Prevalence of QT interval prolonging drug-drug interactions (QT-DDIs) in psychiatry wards of tertiary care hospitals in Pakistan: a multicenter cross-sectional study.

Authors:  Qasim Khan; Mohammad Ismail; Iqbal Haider; Fahadullah Khan
Journal:  Int J Clin Pharm       Date:  2017-09-12

3.  Comparative performance of two drug interaction screening programmes analysing a cross-sectional prescription dataset of 84,625 psychiatric inpatients.

Authors:  Olesya I Zorina; Patrick Haueis; Waldemar Greil; Renate Grohmann; Gerd A Kullak-Ublick; Stefan Russmann
Journal:  Drug Saf       Date:  2013-04       Impact factor: 5.606

4.  Frequency of use of QT-interval prolonging drugs in psychiatry in Belgium.

Authors:  Eline Vandael; Thomas Marynissen; Johan Reyntens; Isabel Spriet; Joris Vandenberghe; Rik Willems; Veerle Foulon
Journal:  Int J Clin Pharm       Date:  2014-05-08

5.  Mono- and combination drug therapies in hospitalized patients with bipolar depression. Data from the European drug surveillance program AMSP.

Authors:  Anne Haeberle; Waldemar Greil; Stefan Russmann; Renate Grohmann
Journal:  BMC Psychiatry       Date:  2012-09-21       Impact factor: 3.630

6.  Unmet challenges in treating hypertension in patients with borderline personality disorder: A systematic review.

Authors:  Saara M Roininen; Marcus Cheetham; Beatrice U Mueller; Edouard Battegay
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

7.  Top 20 drug - drug interactions, polypharmacy and analysis of the nature of risk factors due to QT interval prolonging drug use in elderly psychiatry outpatients.

Authors:  Biswadeep Das; Saravana Kumar Ramasubbu; Barun Kumar; Vikram Singh Rawat
Journal:  J Family Med Prim Care       Date:  2020-12-31

Review 8.  The Influence of Pharmacogenetics on the Clinical Relevance of Pharmacokinetic Drug-Drug Interactions: Drug-Gene, Drug-Gene-Gene and Drug-Drug-Gene Interactions.

Authors:  Martina Hahn; Sibylle C Roll
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-20

9.  Potential drug-drug interactions in prescriptions to patients over 45 years of age in primary care, southern Brazil.

Authors:  Jorge Juarez Vieira Teixeira; Márcia Terezinha Lonardoni Crozatti; Carlos Aparecido dos Santos; Nicolina Silvana Romano-Lieber
Journal:  PLoS One       Date:  2012-10-10       Impact factor: 3.240

10.  Co-Prescription of QT-Interval Prolonging Drugs: An Analysis in a Large Cohort of Geriatric Patients.

Authors:  Simone Schächtele; Thomas Tümena; Karl-Günter Gaßmann; Martin F Fromm; Renke Maas
Journal:  PLoS One       Date:  2016-05-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.